A dose eficaz de bevacizumab para o tratamento da retinopatia da prematuridade

Dikci, Seyhan; Ceylan, Osman Melih; Demirel, Soner; Yılmaz, Turgut

Contact

Submission

Youtube

Open Access

Peer-Reviewed
Carta ao Editor

Response: effective dose of bevacizumab for the treatment of retinopathy of prematurity

A dose eficaz de bevacizumab para o tratamento da retinopatia da prematuridade

Seyhan Dikci; Osman Melih Ceylan; Soner Demirel; Turgut Yılmaz

Dear Editor,

Unfortunately, certain definitions that we use in the terminology of retinopathy of prematurity are still subjective definitions such as plus or pre-plus disease. Therefore, it is difficult to compare among studies in terms of patient characteristics^(1,2). Hence, as the authors point out, it is possible that decisions regarding the primary or additional treatment can differ among physicians. Both groups in our study exhibited posterior zone 2 retinopathy of prematurity in all cases. The systemic side effects of intravitreal anti-VEGF administration in the treatment of retinopathy of prematurity are still unclear. Hence, we are cautious about this treatment in our clinic. However, these results were our early clinical experience, and we wanted to share it. We thank Şahin et al. for their worthy contribution to our article⁽³⁾.

REFERENCES

1. Kemps PS, VanderVeen DK. Computer-assisted digital ımage analysis of plus disease in retinopathy of prematurity. Semin Ophthalmol. 2016;31(1-2):159-62.

2. Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382(9902):1445-57.

3. Dikci S, Ceylan OM, Demirel S, Yılmaz T. Which döşe of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose? Arq Bras Oftalmol. 2018; 81(1):12-7. doi:10.5935/0004-2749.20180005.